Prashant Kapoor

Hematology | Oncology

200 1st St SW
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 431 publications

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

Journal: The New England journal of medicine

Published: July 15, 2026

SOHO State-of-the-Art Updates and Next Questions: Current Approach to Waldenström Macroglobulinemia.

SOHO State-of-the-Art Updates and Next Questions: Current Approach to Waldenström Macroglobulinemia.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 25, 2026

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Journal: American journal of hematology

Published: May 30, 2026

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Journal: Research square

Published: April 17, 2026

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: April 14, 2026

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.

Journal: Blood advances

Published: April 07, 2026

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Journal: Blood advances

Published: April 07, 2026

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

Early Treatment Failure in Patients Receiving Ciltacabtagene-Autoleucel for Relapsed/Refractory Multiple Myeloma.

Journal: American journal of hematology

Published: March 31, 2026

Self-Reported Geriatric Impairments and Treatment Toxicity in Older Patients with Multiple Myeloma-A Single Center Prospective Study.

Self-Reported Geriatric Impairments and Treatment Toxicity in Older Patients with Multiple Myeloma-A Single Center Prospective Study.

Journal: Blood advances

Published: March 31, 2026

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

Journal: American journal of hematology

Published: March 31, 2026

Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma.

Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma.

Journal: Research square

Published: March 27, 2026

High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.

High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.

Journal: British journal of haematology

Published: March 23, 2026

Showing 1-12 of 431

Last Updated: 09/26/2026